FDA approvals - June 2026
New options emerged in MRI contrast imaging, complicated urinary tract infections, and thyroid eye disease.
Featured
22 stories
Make us preferred on GoogleLatest stories
Page 1 of 2
FDA approvals - May 2026
New options emerged in ESR1-mutated breast cancer, mantle cell lymphoma, uncontrolled hypertension, hepatitis delta, and complicated urinary tract infections.
FDA approves Gilead's Hepcludex as the first treatment for chronic hepatitis delta
The first-in-class entry inhibitor cleared a 48%-versus-2% Week 48 virologic and biochemical response — reaching US patients three years after the FDA turned down the original 2 mg dose.
eSpraye (Pulmonary fibrosis, Dry Powder) - Onyx Analyst
Dr. Adil Ali asks Dr. John Patton (CSO) and Dan Miller (Formulation Development Lead) all about eSpraye's drug pipeline.
FDA approvals - March 2026
New options emerged in PBC-associated itch, plaque psoriasis, neurologic Hunter syndrome, and platinum-resistant ovarian cancer.
FDA approvals - January 2026
Copper replacement formalizes care for a fatal pediatric metabolic disorder.
FDA approvals - December 2025
The winter batch of FDA approvals featured therapies that compress intervention into fewer doses, fewer visits, and fewer points of failure.
FDA Approvals - November 2025
Mitochondrial disease and mutant leukemias signal where specialty pharma is placing its biggest bets.
FDA approvals - October 2025
Scarred lungs and hot flashes are two FDA wins for specialty pharma.
Four years of progression-free survival: Nuvation Bio wins FDA approval for lung cancer
With a median progression-free survival nearing four years in ROS1 lung cancer, Nuvation Bio’s breakthrough therapy signals a turning point for precision oncology - validating Dr. David Hung’s patient-first vision.
FDA approvals - September 2025
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
New CEO of Kindbody David Stern is in the business of building families
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
From sickness to prevention: How welfare cuts risk undermining the UK's 10-Year Health Plan
“Preventative care spending fell from 14.1% to just 5.2% of Government healthcare spending.” Ben Phillips warns that welfare reforms could widen existing health gaps.
Moloch and Medicine: why good intentions built a broken system, and why CGT might fix it all (sort of)
Anis Fahandej-Sadi breaks down the big problems with current incentive structures
When is JPM Week 2026?
All the details on when the 44th annual J.P. Morgan Healthcare Conference takes place!
